申请人:Eli Lilly and Company
公开号:US06645976B1
公开(公告)日:2003-11-11
A class of novel indolizine-1-functional compounds and indolizine-3-functional compounds is disclosed together with the use of such indolizine compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock. The compounds are indolizine-1-acetamides, indolizine-1-acetic acid hydrazides, indolizine-1-glyoxylamides, indolizine-3-acetamides, indolizine-3-acetic acid hydraxides, and indolizine-3-glyoxylasides.
一类新型的吲哚啉-1-官能化合物和吲哚啉-3-官能化合物被揭示,以及利用这些吲哚啉化合物来抑制sPLA2介导的脂肪酸释放,用于治疗诸如感染性休克等疾病。这些化合物包括吲哚啉-1-乙酰胺、吲哚啉-1-乙酸肼、吲哚啉-1-甘氧胺、吲哚啉-3-乙酰胺、吲哚啉-3-乙酸肼和吲哚啉-3-甘氧胺。